NuTissu has successfully completed Phase 1 of the Health Innovation Award they received for the E-Plaster® development in 2023, from the Office for Veterans and the Defence and Security Accelerator (DASA).

NuTissu team are focused on offering technology solutions to restore rapid resilience and well-being for the wounded, as well as to release capacity and resources in the healthcare services with technology to facilitate increased efficiency.

The completion of Phase 1 marks a significant step towards clinical adoption, demonstrating the dedication, expertise, and vision of the NuTissu team as well as the transformative potential of E-Plaster® in revolutionizing wound care.

NuTissu team gratefully acknowledge the Health Innovation Awards committee, the Office for Veterans’ team and DASA for recognizing and supporting NuTissu’s vision for next-generation healthcare solutions. Their commitment to fostering innovation has been instrumental in advancing NuTissu’s journey towards commercialisation.

With Phase1 now complete, NuTissu is actively preparing for the next stages, and are focusing to ensure compliance with medical device standards of E-Plaster®, engaging with early adopters for NuTissu-X™ and exploring opportunities for strategic partnerships to accelerate commercialization.

NuTissu team welcome collaborations with healthcare providers, industry partners, and investors who share the company’s vision for smarter, more efficient wound care solutions

Stay tuned for further updates as NuTissu continues to drive innovation in digital wound care technology with patient centric healthcare pathways.